MOR.DE
Price:
$67.25
Market Cap:
$2.53B
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a ...[Read more]
Industry
Biotechnology
IPO Date
1999-03-10
Stock Exchange
XETRA
Ticker
MOR.DE
According to MorphoSys AG’s latest financial reports and current stock price. The company's current Current Ratio is 1.38. This represents a change of -50.46% compared to the average of 2.79 of the last 4 quarters.
The mean historical Current Ratio of MorphoSys AG over the last ten years is 6.64. The current 1.38 Current Ratio has changed 1.98% with respect to the historical average. Over the past ten years (40 quarters), MOR.DE's Current Ratio was at its highest in in the March 2020 quarter at 12.87. The Current Ratio was at its lowest in in the March 2024 quarter at 1.38.
Average
6.64
Median
6.58
Minimum
3.08
Maximum
10.93
Discovering the peaks and valleys of MorphoSys AG Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 22.03%
Maximum Annual Current Ratio = 10.93
Minimum Annual Increase = -41.74%
Minimum Annual Current Ratio = 3.08
Year | Current Ratio | Change |
---|---|---|
2023 | 3.08 | -21.28% |
2022 | 3.91 | -1.74% |
2021 | 3.98 | -33.86% |
2020 | 6.02 | 22.03% |
2019 | 4.93 | -41.74% |
2018 | 8.47 | 18.57% |
2017 | 7.14 | -11.20% |
2016 | 8.04 | -26.38% |
2015 | 10.93 | 10.82% |
2014 | 9.86 | -14.15% |
The current Current Ratio of MorphoSys AG (MOR.DE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.66
5-year avg
4.39
10-year avg
6.64
MorphoSys AG’s Current Ratio is less than Evotec SE (1.83), less than Qiagen N.V. (1.77), greater than United Internet AG (1.06), less than Bechtle AG (1.95), less than Jenoptik AG (2.15),
Company | Current Ratio | Market cap |
---|---|---|
1.83 | $1.51B | |
1.77 | $8.86B | |
1.06 | $3.30B | |
1.95 | $4.02B | |
2.15 | $1.24B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MorphoSys AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MorphoSys AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is MorphoSys AG's Current Ratio?
How is the Current Ratio calculated for MorphoSys AG (MOR.DE)?
What is the highest Current Ratio for MorphoSys AG (MOR.DE)?
What is the 3-year average Current Ratio for MorphoSys AG (MOR.DE)?
What is the 5-year average Current Ratio for MorphoSys AG (MOR.DE)?
How does the current Current Ratio for MorphoSys AG (MOR.DE) compare to its historical average?